

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/025653-2021>

Planning

## **Primary Blood Grouping Managed Service**

NHS Blood and Transplant

F01: Prior information notice

Prior information only

Notice identifier: 2021/S 000-025653

Procurement identifier (OCID): ocids-h6vhtk-02eba2

Published 14 October 2021, 9:31am

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

NHS Blood and Transplant

500 North Bristol Park

Bristol

BS34 7QH

#### **Contact**

Paul Jones

#### **Email**

[paul.jones@nhsbt.nhs.uk](mailto:paul.jones@nhsbt.nhs.uk)

#### **Country**

United Kingdom

#### **NUTS code**

UKK11 - Bristol, City of

**National registration number**

NHS Blood and Transplant

**Internet address(es)**

Main address

<https://www.nhsbt.nhs.uk/>

Buyer's address

<https://www.nhsbt.nhs.uk/>

**I.3) Communication**

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Health

---

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title**

Primary Blood Grouping Managed Service

Reference number

NHSBT1476

### **II.1.2) Main CPV code**

- 73430000 - Test and evaluation

### **II.1.3) Type of contract**

Services

### **II.1.4) Short description**

This Prior Information Notice (PIN) follows 2020/S 247-615598 released on the 15 December 2020 and all information herein supersedes that of 2020/S 247-615598. This Prior Information Notice (PIN) is separate to any tender opportunity and not related in any form whatsoever to any subsequent activity that NHSBT may wish to pursue. The purpose of this PIN is to consult the market to improve NHSBT's knowledge on the status of manufacturer(s) or economic operator(s) that can supply a commercially available automated, high-throughput blood and non-blood group testing equipment and gauge market interest in a new provision of this service. It is the intention of NHSBT to further consult and engage with only those manufacturer(s) and economic operator(s) who meet the outline requirements.

### **II.1.5) Estimated total value**

Value excluding VAT: £30,000,000

### **II.1.6) Information about lots**

This contract is divided into lots: No

## **II.2) Description**

### **II.2.2) Additional CPV code(s)**

- 38434520 - Blood analysers
- 33696200 - Blood-testing reagents
- 48921000 - Automation system
- 71632000 - Technical testing services
- 85111810 - Blood analysis services

### **II.2.3) Place of performance**

## NUTS codes

- UK - United Kingdom

**II.2.4) Description of the procurement**

NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All invitro diagnostic medical devices, for example, instruments, consumables and reagents must be CE/UKCA marked. GB will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system (PULSE) without the need for changes to PULSE. The testing equipment should also be compatible with NHSBT's manufactured reagents and where possible, with those from third party reagent suppliers. NHSBT require a high throughput blood and non-blood donation screening for primary blood grouping testing system(s), for ABO and Rh D typing (as a minimum DIV, DV and DVI), antibody screening and red cell phenotyping including Rh for donor blood samples. As a minimum, the test system supplied must be capable of undertaking the testing of blood and non-blood donor samples and providing accurate results for the following:

- ABO group
- Rh phenotype D, C, c, E, e
- Kell
- Atypical antibody screen
- High titre anti-A and anti-B screening
- Red cell phenotypes S, s, Jka, Jkb (test system should include an option of Cw and M)

All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (<https://www.transfusionguidelines.org/red-book>) and rules and guidance for pharmaceutical manufacturers and distributors. The annual estimated throughput of the NHSBT primary automated blood sample testing equipment tests approximately 1,500,000 donations (of which ca. 1500 - 2100 are non-blood donors) are tested per annum across two NHSBT testing sites, namely Manchester and Filton. Expressions of interest should be e-mailed to [paul.jones@nhsbt.nhs.uk](mailto:paul.jones@nhsbt.nhs.uk) by no later than 1200 hours on 27 October 2021.

**II.3) Estimated date of publication of contract notice**

14 October 2021

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No